The lack of effect on QoL and oxygen consumption help cement the idea that the disease isn’t the same as obstructive HCM.

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

Ferhaan Ahmad, M.D., Ph.D., FAHA, founder of the Cardiovascular Genetics Program at the University of Iowa Carver College of ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) turned out to be a conclusive f | ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

The randomized, double-blind, placebo-controlled ODYSSEY-HCM trial included 580 adult patients with symptomatic nonobstructive HCM.

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Researchers have found that patients with stage B heart failure characteristics and type 2 diabetes have impaired functional capacity.

The following is a summary of "Incidence of Clinically Significant Ventricular Arrhythmias in Patients on Home Inotrope Infusion in the Contemporary Era," published in the March 2025 issue of American ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion opportunity in a label expansion Camzyos.